WallStSmart

DiaMedica Therapeutics Inc (DMAC)vsRegeneron Pharmaceuticals Inc (REGN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

REGN leads profitability with a 28.5% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 80/100 (B+).

DMAC

Avoid

20

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.5
Piotroski: 2/9Altman Z: 1.78

REGN

Strong Buy

80

out of 100

Grade: B+

Growth: 8.7Profit: 8.0Value: 7.3Quality: 8.5
Piotroski: 2/9Altman Z: 4.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DMAC.

REGNUndervalued (+36.3%)

Margin of Safety

+36.3%

Fair Value

$1500.88

Current Price

$952.40

$548.48 discount

UndervaluedFair: $1500.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DMAC1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

REGN6 strengths · Avg: 9.7/10
Operating MarginProfitability
30.4%10/10

Strong operational efficiency at 30.4%

Revenue GrowthGrowth
36.3%10/10

Revenue surging 36.3% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4410/10

Safe zone — low bankruptcy risk

Market CapQuality
$98.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.5%9/10

Keeps 29 of every $100 in revenue as profit

Areas to Watch

DMAC4 concerns · Avg: 4.0/10
Price/BookValuation
15.7x4/10

Trading at 15.7x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

REGN1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DMAC

The strongest argument for DMAC centers on Debt/Equity.

Bull Case : REGN

The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.

Bear Case : DMAC

The primary concerns for DMAC are Price/Book, Revenue Growth, EPS Growth.

Bear Case : REGN

The primary concerns for REGN are Piotroski F-Score.

Key Dynamics to Monitor

DMAC profiles as a value stock while REGN is a growth play — different risk/reward profiles.

DMAC carries more volatility with a beta of 0.94 — expect wider price swings.

REGN is growing revenue faster at 36.3% — sustainability is the question.

REGN generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

REGN scores higher overall (80/100 vs 20/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DiaMedica Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.

Regeneron Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Want to dig deeper into these stocks?